EXOZYMES INC. Amortization
EXOZYMES INC. (EXOZ) reported Amortization of -$23.98 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AdjustmentForAmortization · last filed 2026-08-13
- EXOZYMES INC. amortization for the quarter ending 2026-06-30 was -$11.99K.
- EXOZYMES INC. amortization for the quarter ending 2026-03-31 was -$11.99K.
- EXOZYMES INC. amortization for the quarter ending 2025-12-31 was -$12.70K.
- EXOZYMES INC. amortization for the quarter ending 2025-09-30 was -$13.05K.
- EXOZYMES INC. amortization for fiscal 2025 was -$52.91K.
- EXOZYMES INC. amortization for fiscal 2024 was -$54.36K.
- EXOZYMES INC. amortization for fiscal 2023 was -$51.84K.
| Period end | Amortization 3 month | Amortization 6 month | Amortization 9 month | Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$23.98K 10-Q · filed 2026-08-13 | -$36.68K derived: sum of 3 quarters · filed 2026-08-13 | -$49.74K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$11.99K 10-Q · filed 2026-05-14 | -$24.69K derived: sum of 2 quarters · filed 2026-05-14 | -$37.75K derived: sum of 3 quarters · filed 2026-05-14 | -$51.45K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$12.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$25.75K derived: sum of 2 quarters · filed 2026-03-30 | -$39.46K derived: sum of 3 quarters · filed 2026-08-13 | -$52.91K 10-K · filed 2026-03-30 |
| 2025-09-30 | -$13.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$26.76K derived: sum of 2 quarters · filed 2026-08-13 | -$40.21K 10-Q · filed 2025-11-13 | -$53.67K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$13.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$27.16K 10-Q · filed 2026-08-13 | -$40.61K derived: sum of 3 quarters · filed 2026-08-13 | -$55.07K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$13.46K 10-Q · filed 2026-05-14 | -$26.91K derived: sum of 2 quarters · filed 2026-05-14 | -$41.36K derived: sum of 3 quarters · filed 2026-05-14 | -$54.64K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$13.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$27.91K derived: sum of 2 quarters · filed 2026-03-30 | -$41.19K derived: sum of 3 quarters · filed 2026-03-30 | -$54.36K 10-K · filed 2026-03-30 |
| 2024-09-30 | -$14.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$27.73K derived: sum of 2 quarters · filed 2025-11-13 | -$40.90K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$13.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$26.45K 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$13.17K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$51.84K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |